ATEC Q3 2026 slides show profitability surge despite execution gaps
Alphatec Holdings (ATEC) reported Q3 2026 revenue of $221M, missing estimates, but showed profitability improvements with adjusted EBITDA of $38M. Shares fell 29.46% after hours to $8.02. The company lowered its full-year outlook due to execution challenges, including weaker biologics attachment rates and softer procedure mix.
How this was made
The 30-second read
Why it matters
The trade-off highlighted by the article is profitability expansion versus weaker revenue capture (lower biologics attachment and softer procedure mix), culminating in a guidance reset and a sharp after-hours selloff.
Market read
Traders get a fresh catalyst: Q3 print plus a full-year guidance reduction, with the market reacting to execution risk even as margins improve.
What to watch
Investors may be over-weighting the biologics attachment weakness versus the record surgeon additions and EOS adoption, which could translate into improved attachment rates in subsequent quarters.
Background
Alphatec Holdings (ATEC) delivered Q3 2026 results with record surgeon adoption and strong operating leverage, but missed revenue/EPS expectations and lowered full-year guidance.
Ticker impact
ATEC reported Q3 2026 revenue of $221M and adjusted EPS $0.09, missed consensus, and cut full-year guidance while margins surged.
Likely near-term downside or choppy trading as investors reprice execution risk versus the margin upside.
The article ties the after-hours drop to the revenue per case decline, weaker biologics attachment, and guidance reduction, despite gross margin and EBITDA margin expansion.
Market effects
Signals that spine surgery medtech investors are rewarding margin scalability but penalizing revenue monetization gaps, especially biologics attachment.
No specific regional impact described beyond mention of an international supply issue affecting Q4 guidance.
Limited global read-through; the key driver is company-specific execution and guidance.
Counterpoint
The margin expansion and positive free cash flow trend suggest the business model is working, and the revenue miss may be temporary (management cites execution and a temporary international supply issue).
Key entities
- companyAlphatec Holdings
Spine surgery technology company reporting Q3 2026 results, margin expansion, and a full-year guidance cut.
- personPat Miles
Chairman and CEO cited confidence in underlying fundamentals and execution plans.
- personTodd Koning
CFO presenting the Q3 2026 results and outlook.
